First Affiliated Hospital of Zhejiang University

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

125

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

16 drugs in development

Approved2

Phase 33

Phase 28

Phase 13

Preclinical3

By Therapeutic Area

top 6

Oncology

1158%

Psychiatry

15%

Nephrology

15%

Infectious Disease

15%

Neurology

15%

Immunology

15%

R&D Momentum

75/100

Pipeline Velocity

47/100

Trial Completion Rate

85/100

Pipeline Concentration

37/100

Pipeline Freshness

66/100

Strategic Signals

↗Active in Psychiatry but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 11, 2026

Enrolling by invitation

Effect and Safety of Non-invasive Electrical Stimulation in Improving Cognitive and Depressive Symptoms in Alzheimer's Disease

Jul 8, 2026

Recruiting

Prospective Multicenter Randomized Study of Ruxolitinib Plus Etanercept vs Ruxolitinib Alone for Corticosteroid-Refractory Severe Acute GVHD After Allogeneic HSCT

Earlier

Jun 30, 2026TrialEffect of Different Administration Timing of G-CSF on Peripheral Blood CD34+ Cell Mobilization in Healthy Donors: A Prospective Multicenter Randomized Controlled Trial

Jun 26, 2026TrialEfficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Mar 1, 2026TrialFludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

Feb 9, 2026TrialRemimazolam for Bronchoscopy in High-Risk Patients

Feb 1, 2026TrialNeoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

Jan 25, 2026TrialGilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML

3 more events

Jan 1, 2026TrialSafety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy

Dec 16, 2025TrialComparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT

Dec 3, 2025TrialFirst-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD)

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Immunology(1 drug)

—

Immunology(1 drug)

Infectious Disease(1 drug)

—

Infectious Disease(1 drug)

Nephrology(1 drug)

—

Nephrology(1 drug)

Neurology(1 drug)

—

Neurology(1 drug)

Oncology(11 drugs)

—

Oncology(11 drugs)

Psychiatry(1 drug)

—

Psychiatry(1 drug)

Unknown / Other(3 drugs)

—

Unknown / Other(3 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)